These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31809308)

  • 41. Impact of Male Partner Involvement on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention Trial.
    Roberts ST; Nair G; Baeten JM; Palanee-Philips T; Schwartz K; Reddy K; Kabwigu S; Matovu Kiweewa F; Govender V; Gaffoor Z; Singh N; Siva S; Naidoo K; Montgomery ET;
    AIDS Behav; 2020 May; 24(5):1432-1442. PubMed ID: 31667678
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The sheep as a model of preclinical safety and pharmacokinetic evaluations of candidate microbicides.
    Holt JD; Cameron D; Dias N; Holding J; Muntendam A; Oostebring F; Dreier P; Rohan L; Nuttall J
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3761-70. PubMed ID: 25845860
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women.
    Nel A; Haazen W; Nuttall J; Romano J; Rosenberg Z; van Niekerk N
    AIDS; 2014 Jun; 28(10):1479-87. PubMed ID: 24901365
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development and pharmacokinetics of a combination vaginal ring for sustained release of dapivirine and the protein microbicide 5P12-RANTES.
    McBride JW; Malcolm RK; Dias N; Cameron D; Offord RE; Hartley O; Kett VL; Devlin B; Boyd P
    Int J Pharm; 2019 Jun; 564():207-213. PubMed ID: 30999049
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of Dapivirine Transfer into Blood Plasma, Breast Milk, and Cervicovaginal Fluid of Lactating Women Using the Dapivirine Vaginal Ring.
    Noguchi LM; Hoesley C; Kelly C; Scheckter R; Bunge K; Nel A; Marzinke MA; Hendrix CW; Dezzutti CS; Hillier SL; Bogen DL; Piper JM; Beigi RH
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30602513
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of Women's Home Environment on Use of the Dapivirine Vaginal Ring for HIV Prevention in Sub-Saharan Africa.
    Gichane MW; Katz AWK; Ngure K; Scheckter R; Woeber K; Reddy K; Tauya T; Zimba C; Etima J; Mangxilana N; Palanee-Phillips T; van der Straten A;
    AIDS Behav; 2021 Dec; 25(12):3847-3857. PubMed ID: 34009480
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc.
    Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Gunawardana M; Dawson LN; Olive TJ; Pyles RB; Baum MM
    PLoS One; 2018; 13(8):e0201952. PubMed ID: 30133534
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Power of the Shared Experience: MTN-020/ASPIRE Trial Participants' Descriptions of Peer Influence on Acceptability of and Adherence to the Dapivirine Vaginal Ring for HIV Prevention.
    Katz AWK; Naidoo K; Reddy K; Chitukuta M; Nabukeera J; Siva S; Zimba C; Montgomery ET
    AIDS Behav; 2020 Aug; 24(8):2387-2399. PubMed ID: 31980993
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increases in HIV Incidence Following Receptive Anal Intercourse Among Women: A Systematic Review and Meta-analysis.
    Stannah J; Silhol R; Elmes J; Owen B; Shacklett BL; Anton P; McGowan I; van der Straten A; Dimitrov D; Baggaley RF; Boily MC
    AIDS Behav; 2020 Mar; 24(3):667-681. PubMed ID: 31486008
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of dapivirine vaginal ring use on cervicovaginal immunity and functional microbiome in adolescent girls.
    Farr Zuend C; Noël-Romas L; Hoger S; McCorriser S; Westmacott G; Marrazzo J; Hillier SL; Dezzutti C; Squires K; Bunge KE; Burgener A
    AIDS; 2021 Mar; 35(3):369-380. PubMed ID: 33181534
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Men's Sexual Experiences with the Dapivirine Vaginal Ring in Malawi, South Africa, Uganda and Zimbabwe.
    Montgomery ET; Katz AWK; Duby Z; Mansoor LE; Morar NS; Naidoo K; Tsidya M; Chitukuta M; Guma V; Tenza S; Leslie J; Garcia M; Naidoo S
    AIDS Behav; 2021 Jun; 25(6):1890-1900. PubMed ID: 33389318
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adherence and Acceptability of a Multidrug Vaginal Ring for HIV Prevention in a Phase I Study in the United States.
    van der Straten A; Panther L; Laborde N; Hoesley CJ; Cheng H; Husnik MJ; Horn S; Nel A; Soto-Torres L; Chen BA
    AIDS Behav; 2016 Nov; 20(11):2644-2653. PubMed ID: 26837628
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Randomized, Double Blind, Placebo-Controlled, Phase 1 Safety, and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults (MTN-026).
    Cranston RD; Brown E; Bauermeister J; Dunne EF; Hoesley C; Ho K; Johnson S; Lucas J; Dominguez-Islas C; Gundacker H; Peda M; Jacobson CE; Kramzer L; Singh D; Dezzutti CS; Kunjara Na Ayudhya RP; Brand RM; Wang L; Marzinke MA; Piper J; Devlin B; Nuttall J; McGowan I; Hendrix CW
    AIDS Res Hum Retroviruses; 2022 Apr; 38(4):257-268. PubMed ID: 34498980
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Correlates of Dapivirine Vaginal Ring Acceptance among Women Participating in an Open Label Extension Trial.
    Mirembe BG; Cabrera MV; van der Straten A; Nakalega R; Cobbing M; Mgodi NM; Palanee-Phillips T; Mayo AJ; Dadabhai S; Mansoor LE; Siva S; Nair G; Chinula L; Akello CA; Nakabiito C; Soto-Torres LE; Baeten JM; Brown ER
    AIDS Behav; 2023 Mar; 27(3):1030-1043. PubMed ID: 36066762
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessment of risk compensation following use of the dapivirine vaginal ring in southwestern Uganda.
    Kusemererwa S; Abaasa A; Kabarambi A; Onyango M; Mugisha JO
    Sex Transm Infect; 2022 Feb; 98(1):32-37. PubMed ID: 33542153
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Implementation of a Novel Adherence Monitoring Strategy in a Phase III, Blinded, Placebo-Controlled, HIV-1 Prevention Clinical Trial.
    Husnik MJ; Brown ER; Marzinke M; Livant E; Palanee-Phillips T; Hendrix CW; Matovu Kiweewa F; Nair G; Soto-Torres LE; Schwartz K; Hillier SL; Baeten JM;
    J Acquir Immune Defic Syndr; 2017 Nov; 76(3):330-337. PubMed ID: 28746164
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HIV-1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial.
    Parikh UM; Penrose KJ; Heaps AL; Halvas EK; Goetz BJ; Gordon KC; Hardesty R; Sethi R; Schwarzmann W; Szydlo DW; Husnik MJ; Chandran U; Palanee-Phillips T; Baeten JM; Mellors JW;
    J Int AIDS Soc; 2021 Nov; 24(11):e25833. PubMed ID: 34762770
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HIV prevention at drug shops: awareness and attitudes among shop dispensers and young women about oral pre-exposure prophylaxis and the dapivirine ring in Shinyanga, Tanzania.
    Tubert J; Packel L; Hunter LA; Mfaume R; Njau P; Ramadhani AA; Liu JX; McCoy SI
    AIDS Res Ther; 2021 Apr; 18(1):21. PubMed ID: 33902623
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Experiences with simultaneous use of contraception and the vaginal ring for HIV prevention in sub-Saharan Africa.
    Leslie J; Kiweewa F; Palanee-Phillips T; Bunge K; Mhlanga F; Kamira B; Baeten J; Katz A; Hillier S; Montgomery E;
    BMC Womens Health; 2021 Apr; 21(1):175. PubMed ID: 33892693
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The future role of rectal and vaginal microbicides to prevent HIV infection in heterosexual populations: implications for product development and prevention.
    Boily MC; Dimitrov D; Abdool Karim SS; Mâsse B
    Sex Transm Infect; 2011 Dec; 87(7):646-53. PubMed ID: 22110117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.